Committed to building a world-class molecular diagnosis company
One of the innovative leaders in domestic genetic testing, molecular diagnosis, Tianlong in order to better serve medical diagnosis, biological testing, individualized medical, food safety and inspection and quarantine, life science, medical research and medical training, etc. It has now been developed to have a company group with a number of subsidiaries such as Tianlong, Suzhou Tianlong, Wuxi Qiqi, becoming in vitro diagnostic products.+Third-party medical inspection service+The comprehensive service provider of the whole chain of hospital investment.
As the market development needs and the company's products are constantly rich, the company has established the Clinical Division, Life Science Division, Overseas Division, Hosting and Regional Building Project.
Multiple business sections such as tumor individualization drug project department.
On November 25th, Jiangsu Provincial Productivity Promotion Center released the results of the 20021 Jiangsu High-tech Zone Unicorn Enterprise and Yelong Enterprise Assessment, Suzhou Tianlong Biotechnology Co., Ltd. was selected in the \"2021 Yelong Enterprise\" list.
Tianlong Technology is based on market-oriented, and has been based on the research and development of science and technology, and pursues independent brands. Since its establishment in 1997, the company has consistently adhering to the public, market-oriented, customer-centric development concept, is committed to research and development, production and sales of instruments and in vitro diagnostic reagents in the field of genetic testing, molecular diagnosis. One of the innovative leaders in domestic genetic testing, molecular diagnosis, Tianlong in order to better serve medical diagnosis, biological testing, individualized medical, food safety and inspection and quarantine, life science, medical research and medical training, etc. It has now been developed to have a company group with a number of subsidiaries such as Tianlong, Suzhou Tianlong, Wuxi Qiqi, and become a comprehensive service provider of full-stranded medical health industry in vitro diagnostic products + third-party medical inspection services + hospital investment. . Tianlong takes the world's top 500 in 2012 in 2012
Tianlong's wisdom family adds new members! The \"hepatitis B virus (HBV) nucleic acid test kit (PCR-fluorescent probe method) \" officially developed by Tianlong Technology \"officially won the listing of the National Drug Administration (NMPA), gaining three types of medical device registration certificates . It is worth mentioning that the reagent is a national science and technological major project undertaken by Tianlong Technology \"AIDS and viral hepatitis and other major infectious disease prevention \" - \"viral hepatitis related liver cancer population warning and stove Town kit and related The strategic transformation of equipment development \"(No. 2018ZX10732-202) is therefore a priority approval. National Temporation 20213400869 Ultra-high (emphasis) Product Advantage 1 Detection Sensitive: HBV Detection Limited to 5IU / mL, especially suitable for low viral load patients; L Quantitative precision: HBV quantitative range 15 IU / mL-1.0 × 109IU / M